Steven Cohen’s Moderna MRNA Stock Holding History

Steven Cohen’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.63M	Sell	123,200 -322,900	-72%	-$16.7M	0.01%	1376
2026 Q1	$22.7M	Buy	446,100 +268,100	+151%	+$12.5M	0.03%	736
2025 Q4	$5.25M	Buy	+178,000	New	+$4.84M	0.01%	1814

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Steven Cohen's MRNA Position: Q2 2026 in Review

Steven Cohen sold out of Moderna (MRNA) in Q2 2026, closing a stake of 197,844 shares — an estimated $10.2M sold.

Steven Cohen first reported a position in MRNA in Q4 2018 and held it in 2 quarters. The position peaked at $10.1M in Q1 2026. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Steven Cohen reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 197,844 Moderna shares in Q2 2026, an estimated $10.2M.
Steven Cohen first reported a position in Moderna in Q4 2018 and held it in 2 quarters.
Steven Cohen's Moderna position peaked at $10.1M in Q1 2026.
775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.